EcoDrugPlus

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSMAMG00000014181
Gene Symbol: LOC113144923
2 Cross references
185 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSMAMG00000006563
Gene Symbol: TYR
3 Cross references
202 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSMAMG00000010767
Gene Symbol: TYR
4 Cross references
198 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSMAMG00000003562
Gene Symbol: TH
3 Cross references
187 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSMAMG00000012164
Gene Symbol: TYK2
3 Cross references
195 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin-Like And Egf-Like Domains 1

Ensembl ID : ENSMAMG00000009664
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSMAMG00000001110
Gene Symbol: UTS2R
4 Cross references
97 Possible Orthologues:

Utrophin

Ensembl ID : ENSMAMG00000020956
Gene Symbol: UTRN
2 Cross references
270 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSMAMG00000005606
Gene Symbol: KRAS
3 Cross references
207 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 1

Ensembl ID : ENSMAMG00000007753
Gene Symbol: AKT1
2 Cross references
195 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSMAMG00000002074
Gene Symbol: AKT2
4 Cross references
195 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSMAMG00000021727
Gene Symbol: AKT3A
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).